×
Adocia Long Term Debt 2016-2023 | ADOCY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Adocia long term debt from 2016 to 2023. Long term debt can be defined as the sum of all long term debt fields.
View More
Adocia Long Term Debt 2016-2023 | ADOCY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Adocia long term debt from 2016 to 2023. Long term debt can be defined as the sum of all long term debt fields.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$141B
Bristol Myers Squibb (BMY)
$113.2B
Gilead Sciences (GILD)
$112B
Vertex Pharmaceuticals (VRTX)
$105.5B
CSL (CSLLY)
$84.4B
Regeneron Pharmaceuticals (REGN)
$76.6B
GSK (GSK)
$68.6B
Argenex SE (ARGX)
$39.6B
Alnylam Pharmaceuticals (ALNY)
$30.7B
BioNTech SE (BNTX)
$29.5B
Biogen (BIIB)
$21.7B
Illumina (ILMN)
$21.7B
BeiGene (ONC)
$17.3B
Moderna (MRNA)
$16.3B
Genmab (GNMSF)
$14.7B
Genmab (GMAB)
$14.7B
Incyte (INCY)
$13.6B
BioMarin Pharmaceutical (BMRN)
$12.8B
Sarepta Therapeutics (SRPT)
$11.9B
Insmed (INSM)
$11.7B
Bio-Techne Corp (TECH)
$11.6B
Exact Sciences (EXAS)
$10.5B
Exelixis (EXEL)
$10.3B
QIAGEN (QGEN)
$10.2B
Vaxcyte (PCVX)
$10.1B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Intra-Cellular Therapies (ITCI)
$10.1B
Bio-Rad Laboratories (BIO.B)
$9.5B
Repligen (RGEN)
$8.7B
Ascendis Pharma (ASND)
$7.8B